PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Prothena Reports Second Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $12.2 million in the second quarter and $29.7 million for the first six months of 2019; quarter-end cash and restricted cash position of $402.2 million provides funding to advance neuroscience pipeline Appointed Paula K.
View HTML
Toggle Summary Prothena to Report Second Quarter 2019 Financial Results on August 6
DUBLIN, Ireland , July 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2019 on August 6, 2019 after the close of the U.S. financial markets.
View HTML
Toggle Summary Prothena Announces Appointment of Paula K. Cobb to its Board of Directors
DUBLIN, Ireland , July 01, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Paula Cobb to its Board of Directors. “As a biotechnology executive with wide-ranging global development, business strategy and
View HTML
Toggle Summary Prothena to Participate in the Jefferies Healthcare Conference
DUBLIN, Ireland , May 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the Jefferies Healthcare Conference on June 6 th at 10:30 AM ET in New York,
View HTML
Toggle Summary Prothena Reports First Quarter 2019 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $17.6 million in the first quarter; quarter-end cash and restricted cash position of $414.2 million provides funding to advance neuroscience pipeline Initiated cell line development of a lead candidate for preclinical tau program DUBLIN,
View HTML
Toggle Summary Prothena to Report First Quarter 2019 Financial Results on May 7
DUBLIN, Ireland , April 30, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, will announce financial results for the first quarter of 2019 on May 7, 2019 after the close of the U.S. financial markets.
View HTML
Toggle Summary Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
Results from final analysis of the composite primary endpoint were consistent with the futility analysis reported in April 2018 Results from post hoc analyses revealed a potential survival benefit with NEOD001 in the category of patients at the highest risk for early mortality ( Mayo Stage IV )
View HTML
Toggle Summary Prothena to Participate in Upcoming March Healthcare Conferences
DUBLIN, Ireland , March 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the following March investor conferences:  Barclays Global Healthcare
View HTML
Toggle Summary Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update
Net cash used in operating and investing activities was $22.5 million in the fourth quarter and $30.0 million for the full year 2018; quarter-end cash and restricted cash position of $431.7 million provides funding to advance neuroscience pipeline Entered into global neuroscience research &
View HTML
Toggle Summary Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 14 th , after the close of the U.S. financial markets.
View HTML
Toggle Summary Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018; quarter-end cash and restricted cash position of $455.6 million provides funding to advance neuroscience pipeline DUBLIN, Ireland , Nov.
View HTML
Toggle Summary Prothena to Report Third Quarter 2018 Financial Results on November 6
DUBLIN, Ireland , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of the U.S. financial markets.
View HTML
Toggle Summary Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update
Net loss was $59.9 million in the second quarter and $108.6 million for the first six months ended June 30, 2018 Net cash from operating and investing activities was $58.0 million in the second quarter and  $26.3 million in the first six months of 2018; quarter-end cash and restricted cash position
View HTML
Toggle Summary Prothena to Report Second Quarter 2018 Financial Results on August 7
DUBLIN, Ireland , July 31, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2018 on August 7, 2018 after the close of the U.S. financial markets.
View HTML
Toggle Summary Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer
DUBLIN, Ireland , June 25, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that Tran B. Nguyen has been appointed to the newly created
View HTML